In summary, these results indicated that the recombinant MUC1-MBP vaccine inhibited tumor growth by inducing the MUC1-specific T cell response, and that the weakened T cell responses in mice immunized eight times may be related to a decrease in the tumor suppression rate. This evidence concerns the gene MBP and neoplasm.